Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2010

Open Access 01-12-2010 | Research article

Myc suppression of Nfkb2 accelerates lymphomagenesis

Authors: Ulrich Keller, Jürgen Huber, Jonas A Nilsson, Mohammad Fallahi, Mark A Hall, Christian Peschel, John L Cleveland

Published in: BMC Cancer | Issue 1/2010

Login to get access

Abstract

Background

Deregulated c-Myc expression is a hallmark of several human cancers where it promotes proliferation and an aggressive tumour phenotype. Myc overexpression is associated with reduced activity of Rel/NF-κB, transcription factors that control the immune response, cell survival, and transformation, and that are frequently altered in cancer. The Rel/NF-κB family member NFKB2 is altered by chromosomal translocations or deletions in lymphoid malignancies and deletion of the C-terminal ankyrin domain of NF-κB2 augments lymphocyte proliferation.

Methods

Precancerous Eμ-Myc-transgenic B cells, Eμ-Myc lymphomas and human Burkitt lymphoma samples were assessed for Nfkb2 expression. The contribution of Nfkb2 to Myc-driven apoptosis, proliferation, and lymphomagenesis was tested genetically in vivo.

Results

Here we report that the Myc oncoprotein suppresses Nfkb2 expression in vitro in primary mouse fibroblasts and B cells, and in vivo in the Eμ-Myc transgenic mouse model of human Burkitt lymphoma (BL). NFKB2 suppression by Myc was also confirmed in primary human BL. Promoter-reporter assays indicate that Myc-mediated suppression of Nfkb2 occurs at the level of transcription. The contribution of Nfkb2 to Myc-driven lymphomagenesis was tested in vivo, where Nfkb2 loss was shown to accelerate lymphoma development in Eμ-Myc transgenic mice, by impairing Myc's apoptotic response.

Conclusions

Nfkb2 is suppressed by c-Myc and harnesses Myc-driven lymphomagenesis. These data thus link Myc-driven lymphomagenesis to the non-canonical NF-κB pathway.
Appendix
Available only for authorised users
Literature
1.
Gilmore TD: Introduction to NF-κB: players, pathways, perspectives. Oncogene. 2006, 25 (51): 6680-6684. 10.1038/sj.onc.1209954.CrossRefPubMed
2.
3.
Ghosh S, Karin M: Missing pieces in the NF-κB puzzle. Cell. 2002, 109 (Suppl): S81-96. 10.1016/S0092-8674(02)00703-1.CrossRefPubMed
4.
Senftleben U, Cao Y, Xiao G, Greten FR, Krahn G, Bonizzi G, Chen Y, Hu Y, Fong A, Sun SC, et al: Activation by IKKα of a second, evolutionary conserved, NF-kappa B signaling pathway. Science. 2001, 293 (5534): 1495-1499. 10.1126/science.1062677.CrossRefPubMed
5.
Xiao G, Harhaj EW, Sun SC: NF-κB-inducing kinase regulates the processing of NF-κB2 p100. Mol Cell. 2001, 7 (2): 401-409. 10.1016/S1097-2765(01)00187-3.CrossRefPubMed
6.
Caamano JH, Rizzo CA, Durham SK, Barton DS, Raventos-Suarez C, Snapper CM, Bravo R: Nuclear factor (NF)- κB2 (p100/p52) is required for normal splenic microarchitecture and B cell-mediated immune responses. J Exp Med. 1998, 187 (2): 185-196. 10.1084/jem.187.2.185.CrossRefPubMedPubMedCentral
7.
Orlowski RZ, Baldwin AS: NF-κB as a therapeutic target in cancer. Trends Mol Med. 2002, 8 (8): 385-389. 10.1016/S1471-4914(02)02375-4.CrossRefPubMed
8.
Karin M, Cao Y, Greten FR, Li ZW: NF-κB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002, 2 (4): 301-310. 10.1038/nrc780.CrossRefPubMed
9.
Courtois G, Gilmore TD: Mutations in the NF-κB signaling pathway: implications for human disease. Oncogene. 2006, 25 (51): 6831-6843. 10.1038/sj.onc.1209939.CrossRefPubMed
10.
Rayet B, Gelinas C: Aberrant rel/nfkb genes and activity in human cancer. Oncogene. 1999, 18 (49): 6938-6947. 10.1038/sj.onc.1203221.CrossRefPubMed
11.
Perkins ND: Oncogenes, tumor suppressors and p52 NF-κB. Oncogene. 2003, 22 (48): 7553-7556. 10.1038/sj.onc.1207139.CrossRefPubMed
12.
Chang CC, Zhang J, Lombardi L, Neri A, Dalla-Favera R: Rearranged NFKB-2 genes in lymphoid neoplasms code for constitutively active nuclear transactivators. Mol Cell Biol. 1995, 15 (9): 5180-5187.CrossRefPubMedPubMedCentral
13.
Kim KE, Gu C, Thakur S, Vieira E, Lin JC, Rabson AB: Transcriptional regulatory effects of lymphoma-associated NFKB2/lyt10 protooncogenes. Oncogene. 2000, 19 (10): 1334-1345. 10.1038/sj.onc.1203432.CrossRefPubMed
14.
Ishikawa H, Carrasco D, Claudio E, Ryseck RP, Bravo R: Gastric hyperplasia and increased proliferative responses of lymphocytes in mice lacking the COOH-terminal ankyrin domain of NF-κB2. J Exp Med. 1997, 186 (7): 999-1014. 10.1084/jem.186.7.999.CrossRefPubMedPubMedCentral
15.
Sheiness D, Fanshier L, Bishop JM: Identification of nucleotide sequences which may encode the oncogenic capacity of avian retrovirus MC29. J Virol. 1978, 28 (2): 600-610.PubMedPubMedCentral
16.
Boxer LM, Dang CV: Translocations involving c-myc and c-myc function. Oncogene. 2001, 20 (40): 5595-5610. 10.1038/sj.onc.1204595.CrossRefPubMed
17.
Kelly K, Cochran BH, Stiles CD, Leder P: Cell-specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor. Cell. 1983, 35 (3 Pt 2): 603-610. 10.1016/0092-8674(83)90092-2.CrossRefPubMed
18.
Henriksson M, Luscher B: Proteins of the Myc network: essential regulators of cell growth and differentiation. Adv Cancer Res. 1996, 68: 109-182. full_text.CrossRefPubMed
19.
Nilsson JA, Cleveland JL: Myc pathways provoking cell suicide and cancer. Oncogene. 2003, 22 (56): 9007-9021. 10.1038/sj.onc.1207261.CrossRefPubMed
20.
Grandori C, Cowley SM, James LP, Eisenman RN: The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol. 2000, 16: 653-699. 10.1146/annurev.cellbio.16.1.653.CrossRefPubMed
21.
Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ, Greiner TC, Weisenburger DD, Rosenwald A, Ott G, et al: Molecular diagnosis of Burkitt's lymphoma. N Engl J Med. 2006, 354 (23): 2431-2442. 10.1056/NEJMoa055759.CrossRefPubMed
22.
Keller U, Nilsson JA, Maclean KH, Old JB, Cleveland JL: Nfkb 1 is dispensable for Myc-induced lymphomagenesis. Oncogene. 2005, 24 (41): 6231-6240. 10.1038/sj.onc.1208779.CrossRefPubMed
23.
Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, Palmiter RD, Brinster RL: The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature. 1985, 318 (6046): 533-538. 10.1038/318533a0.CrossRefPubMed
24.
Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL: Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes & development. 1999, 13 (20): 2658-2669. 10.1101/gad.13.20.2658.CrossRef
25.
Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ, Roussel MF: Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes & development. 1998, 12 (15): 2424-2433. 10.1101/gad.12.15.2424.CrossRef
26.
Pajic A, Spitkovsky D, Christoph B, Kempkes B, Schuhmacher M, Staege MS, Brielmeier M, Ellwart J, Kohlhuber F, Bornkamm GW, et al: Cell cycle activation by c-myc in a burkitt lymphoma model cell line. Int J Cancer. 2000, 87 (6): 787-793. 10.1002/1097-0215(20000915)87:6<787::AID-IJC4>3.0.CO;2-6.CrossRefPubMed
27.
Baudino TA, Maclean KH, Brennan J, Parganas E, Yang C, Aslanian A, Lees JA, Sherr CJ, Roussel MF, Cleveland JL: Myc-mediated proliferation and lymphomagenesis, but not apoptosis, are compromised by E2f1 loss. Mol Cell. 2003, 11 (4): 905-914. 10.1016/S1097-2765(03)00102-3.CrossRefPubMed
28.
Frank SR, Schroeder M, Fernandez P, Taubert S, Amati B: Binding of c-Myc to chromatin mediates mitogen-induced acetylation of histone H4 and gene activation. Genes & development. 2001, 15 (16): 2069-2082. 10.1101/gad.906601.CrossRef
29.
Lewis BC, Shim H, Li Q, Wu CS, Lee LA, Maity A, Dang CV: Identification of putative c-Myc-responsive genes: characterization of rcl, a novel growth-related gene. Molecular and cellular biology. 1997, 17 (9): 4967-4978.CrossRefPubMedPubMedCentral
30.
Keller UB, Old JB, Dorsey FC, Nilsson JA, Nilsson L, Maclean KH, Chung L, Yang C, Spruck C, Boyd K, et al: Myc targets Cks1 to provoke the suppression of p27(Kip1), proliferation and lymphomagenesis. Embo J. 2007, 26 (10): 2562-2574. 10.1038/sj.emboj.7601691.CrossRefPubMedPubMedCentral
31.
Liptay S, Schmid RM, Nabel EG, Nabel GJ: Transcriptional regulation of NF-κB2: evidence for κB-mediated positive and negative autoregulation. Molecular and cellular biology. 1994, 14 (12): 7695-7703.CrossRefPubMedPubMedCentral
32.
33.
Qing G, Xiao G: Essential role of IκB kinase-α in the constitutive processing of NF-κB2 p100. The Journal of biological chemistry. 2005, 280 (11): 9765-9768. 10.1074/jbc.C400502200.CrossRefPubMed
34.
Littlewood TD, Hancock DC, Danielian PS, Parker MG, Evan GI: A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic acids research. 1995, 23 (10): 1686-1690. 10.1093/nar/23.10.1686.CrossRefPubMedPubMedCentral
35.
Peukert K, Staller P, Schneider A, Carmichael G, Hanel F, Eilers M: An alternative pathway for gene regulation by Myc. Embo J. 1997, 16 (18): 5672-5686. 10.1093/emboj/16.18.5672.CrossRefPubMedPubMedCentral
36.
Wanzel M, Herold S, Eilers M: Transcriptional repression by Myc. Trends Cell Biol. 2003, 13 (3): 146-150. 10.1016/S0962-8924(03)00003-5.CrossRefPubMed
37.
Staller P, Peukert K, Kiermaier A, Seoane J, Lukas J, Karsunky H, Moroy T, Bartek J, Massague J, Hanel F, et al: Repression of p15INK4b expression by Myc through association with Miz-1. Nat Cell Biol. 2001, 3 (4): 392-399. 10.1038/35070076.CrossRefPubMed
38.
Wu S, Cetinkaya C, Munoz-Alonso MJ, von der Lehr N, Bahram F, Beuger V, Eilers M, Leon J, Larsson LG: Myc represses differentiation-induced p21CIP1 expression via Miz-1-dependent interaction with the p21 core promoter. Oncogene. 2003, 22 (3): 351-360. 10.1038/sj.onc.1206145.CrossRefPubMed
39.
Schmitt CA, McCurrach ME, de Stanchina E, Wallace-Brodeur RR, Lowe SW: INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev. 1999, 13 (20): 2670-2677. 10.1101/gad.13.20.2670.CrossRefPubMedPubMedCentral
40.
Old JB, Kratzat S, Hoellein A, Graf S, Nilsson JA, Nilsson L, Nakayama KI, Peschel C, Cleveland JL, Keller UB: Skp2 directs Myc-mediated suppression of p27Kip1 yet has modest effects on Myc-driven lymphomagenesis. Mol Cancer Res. 2010, 8 (3): 353-362. 10.1158/1541-7786.MCR-09-0232.CrossRefPubMedPubMedCentral
41.
Nilsson JA, Keller UB, Baudino TA, Yang C, Norton S, Old JA, Nilsson LM, Neale G, Kramer DL, Porter CW, et al: Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation. Cancer Cell. 2005, 7 (5): 433-444. 10.1016/j.ccr.2005.03.036.CrossRefPubMed
42.
Perkins ND: NF-κB: tumor promoter or suppressor?. Trends Cell Biol. 2004, 14 (2): 64-69. 10.1016/j.tcb.2003.12.004.CrossRefPubMed
43.
Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth TF, Bernd HW, Cogliatti SB, Dierlamm J, Feller AC, et al: A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006, 354 (23): 2419-2430. 10.1056/NEJMoa055351.CrossRefPubMed
44.
Adhikary S, Eilers M: Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol. 2005, 6 (8): 635-645. 10.1038/nrm1703.CrossRefPubMed
45.
Lee LA, Dang CV: Myc target transcriptomes. Curr Top Microbiol Immunol. 2006, 302: 145-167. full_text.PubMed
46.
Gartel AL, Shchors K: Mechanisms of c-myc-mediated transcriptional repression of growth arrest genes. Exp Cell Res. 2003, 283 (1): 17-21. 10.1016/S0014-4827(02)00020-4.CrossRefPubMed
47.
Coller HA, Grandori C, Tamayo P, Colbert T, Lander ES, Eisenman RN, Golub TR: Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc Natl Acad Sci USA. 2000, 97 (7): 3260-3265. 10.1073/pnas.97.7.3260.CrossRefPubMedPubMedCentral
48.
Bush A, Mateyak M, Dugan K, Obaya A, Adachi S, Sedivy J, Cole M: c-myc null cells misregulate cad and gadd45 but not other proposed c-Myc targets. Genes Dev. 1998, 12 (24): 3797-3802. 10.1101/gad.12.24.3797.CrossRefPubMedPubMedCentral
49.
de Alboran IM, O'Hagan RC, Gartner F, Malynn B, Davidson L, Rickert R, Rajewsky K, DePinho RA, Alt FW: Analysis of c-MYC function in normal cells via conditional gene-targeted mutation. Immunity. 2001, 14 (1): 45-55. 10.1016/S1074-7613(01)00088-7.CrossRefPubMed
50.
Homig-Holzel C, Hojer C, Rastelli J, Casola S, Strobl LJ, Muller W, Quintanilla-Martinez L, Gewies A, Ruland J, Rajewsky K, et al: Constitutive CD40 signaling in B cells selectively activates the noncanonical NF-κB pathway and promotes lymphomagenesis. J Exp Med. 2008, 205 (6): 1317-1329. 10.1084/jem.20080238.CrossRefPubMedPubMedCentral
51.
Wang Z, Zhang B, Yang L, Ding J, Ding HF: Constitutive production of NF-κB2 p52 is not tumorigenic but predisposes mice to inflammatory autoimmune disease by repressing Bim expression. J Biol Chem. 2008, 283 (16): 10698-10706. 10.1074/jbc.M800806200.CrossRefPubMedPubMedCentral
52.
Zhang B, Wang Z, Li T, Tsitsikov EN, Ding HF: NF-κB2 mutation targets TRAF1 to induce lymphomagenesis. Blood. 2007, 110 (2): 743-751. 10.1182/blood-2006-11-058446.CrossRefPubMedPubMedCentral
53.
Klapproth K, Sander S, Marinkovic D, Baumann B, Wirth T: The IKK2/NF-κB pathway suppresses MYC-induced lymphomagenesis. Blood. 2009, 114 (12): 2448-2458. 10.1182/blood-2008-09-181008.CrossRefPubMed
54.
Yang W, Shen J, Wu M, Arsura M, FitzGerald M, Suldan Z, Kim DW, Hofmann CS, Pianetti S, Romieu-Mourez R, et al: Repression of transcription of the p27(Kip1) cyclin-dependent kinase inhibitor gene by c-Myc. Oncogene. 2001, 20 (14): 1688-1702. 10.1038/sj.onc.1204245.CrossRefPubMed
Metadata
Title
Myc suppression of Nfkb2 accelerates lymphomagenesis
Authors
Ulrich Keller
Jürgen Huber
Jonas A Nilsson
Mohammad Fallahi
Mark A Hall
Christian Peschel
John L Cleveland
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2010
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-10-348

Other articles of this Issue 1/2010

BMC Cancer 1/2010 Go to the issue

Research article

High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology

Research article

p27Kip1deficiency promotes prostate carcinogenesis but does not affect the efficacy of retinoids in suppressing the neoplastic process

Research article

Overexpression of S100A4 in human cancer cell lines resistant to methotrexate

Research article

Benign mammary epithelial cells enhance the transformed phenotype of human breast cancer cells

Research article

Periostin is up-regulated in high grade and high stage prostate cancer

Research article

Mutations in the WTX- gene are found in some high-grade microsatellite instable (MSI-H) colorectal cancers
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits